Sat, Aug 30, 2014, 5:12 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Take-Two Interactive Software Inc. Message Board

false 7 posts  |  Last Activity: Aug 26, 2014 9:02 PM Member since: Jul 16, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Is setting a trailing stop to sell a way to protect earnings?
    I've traded MU, twice and made a small profit each time. MU is a robust company and I trust if i goes down a few bucks it will go back up soon but I wait to long to sell. Additionally, I can't watch trading all day.
    I posted on the MU board because I thin

  • PRESS RELEASE
    Aug. 10, 2014, 9:01 a.m. EDT
    CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results


    VIENNA, Va., Aug 10, 2014 (BUSINESS WIRE) -- CEL-SCI Corporation (nyse mkt:CVM) today reported financial results for the quarter ended June 30, 2014.

    Recent key corporate and clinical developments include:

    Enrolled 54 patients in the Company’s Phase III head and neck cancer trial during the quarter, a 93% increase in sequential quarterly patient enrollment; Subsequently in July, achieved milestone of total 232 patients enrolled to date, representing over one-quarter of the total enrollment for the study.

    Added four clinical sites in the U.S. and additional clinical centers around the world for Multikine, an investigational immunotherapy being studied in a global pivotal Phase III head and neck cancer trial .

    Expanded the Phase III head and neck cancer trial into the United Kingdom during the quarter, with additional expansions post-quarter into Austria, Sri Lanka, Turkey and France.

    Raised approximately $9.84 million in net proceeds through the sale of common stock and warrants in a public offering and from the exercise of previously issued and outstanding warrants.

    CEL-SCI reported an operating loss of ($6,901,329) for the quarter ended June 30, 2014 versus an operating loss of ($5,513,199) for the quarter ended June 30, 2013. The operating loss for the nine months ended June 30, 2014 was ($19,062,074) versus ($14,796,535) during the nine months ended June 30, 2013. The rise in operating loss was mostly attributable to an increase in research and development expenses to $12,627,269 in the nine month ended June 30, 2014 compared to $9,208,900 in the nine months ended June 30, 2013. R&D expenses increased because of the expansion of the Company’s Phase III clinical study for head and neck cancer and an associated increase in patient enrollment.

    CEL-SCI's net loss available to common shareholders for the quarter ended June 30, 2014 was ($2,444,480) or ($0.04) per basic share, versus ($4,507,074) or ($0.15) per basic share during the quarter ended June 30, 2013. The net loss available to common shareholders for the nine months ended June 30, 2014 was ($21,261,925) or ($0.38) per basic share, versus ($7,530,621) or ($0.25) per basic share during the same nine months ended June 30, 2013. The increase in net loss for the three and nine month periods of 2014 as compared to the same periods in 2013 was primarily attributable to a non-cash charge for the change in value of derivative instruments caused by the fluctuation in the Company’s common stock share price.

    During the nine months ended June 30, 2014, the Company raised approximately $31.5 million in net proceeds through the sale of common stock and warrants in a public offering and from the exercise of previously issued and outstanding warrants.

    “We enrolled 54 patients in our Phase III head and neck cancer trial for the quarter ended June 30, 2014 which was the best quarter ever for us. Since the end of June, we have added four countries to%2

  • Reply to

    hey Foreman, greg_martin, isthislega1 ……...

    by casecard64 Jul 30, 2014 6:31 PM
    false false Jul 30, 2014 8:20 PM Flag

    Sorry, I'm just a private investor trying to warn new investors of the%2

  • You never see any insider buying in this company. They issue more stock for staff and dilutes the share base and insiders selling the stock on regular basis. It certainly makes you wonder when%2

  • Reply to

    Adam F makes some excellent points

    by colton_harden1 Jun 17, 2014 4:01 PM
    false false Jun 18, 2014 2:09 AM Flag

    Hold fast-
    Yes, I make it a point to read every article and post, no matter how worthless; Its simply a part of my overall research; I read every conference proceeding, every news release, every trial data, etc.

    What has impressed on me more than anything is that the garbage SA or Motley articles, as well as all the posts by bashers on this board are absolutely without merit, shallow. It is clear there is no good ammunition available for the short. He is desperate now. If the statistics detailing the options contracts and short holdings are remotely close to correct, and given the high probability of approval, then there is

  • Hold fast-
    I make it a point to read every article and post, no matter how worthless; Its simply a part of my overall research; I read every conference proceeding, every news release, every trial data, etc.

    What has impressed on me more than anything is that the garbage SA or Motley articles, as well as all the posts by bashers on this board are absolutely without merit, shallow. It is clear there is no good ammunition available for the short. He is desperate now. If the statistics detailing the options contracts and short holdings are r

  • Reply to

    Shorts' desperation is undeniable

    by mangum51 Jun 17, 2014 11:30 PM
    false false Jun 18, 2014 1:28 AM Flag

    Yes, I make it a point to read every article and post, no matter how worthless; Its simply a part of my overall research; I read every conference proceeding, every news release, every trial data, etc.

    What has impressed on me more than anything is that the garbage SA or Motley articles, as well as all the posts by bashers on%2

TTWO
23.51+1.05(+4.67%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.